Form 4: Regeneron EVP Joseph LaRosa Reports Stock Sale Under 10b5-1 Plan

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,865 shares of common stock at $994.90 per share under a pre-arranged 10b5-1 trading plan.

Summary

• On May 21, 2024, Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,865 shares of common stock at a price of $994.90 per share.
• The sale was executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on February 16, 2024.
• Following the transaction, LaRosa directly owns 34,678 shares of Regeneron common stock.
• LaRosa also indirectly owns 3,367 shares through a 2022 GRAT and 371 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often part of pre-arranged trading plans to avoid accusations of insider trading. The use of 10b5-1 plans allows insiders to sell shares at predetermined times and prices, regardless of any material non-public information they may possess.

Comparison to Industry Standards

• Executive stock sales are a common practice across the pharmaceutical industry.
• Companies like Amgen, Pfizer, and Johnson & Johnson also see regular Form 4 filings related to executive stock transactions.
• The use of 10b5-1 trading plans is a standard method for executives to manage their stock holdings while complying with insider trading regulations.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates